Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 1,820 matching trials from the live ClinicalTrials.gov search.
Terminated Phase 2 Interventional Results available

Etanercept for the Treatment of Lupus Nephritis

NCT00447265
Conditions
Lupus Nephritis
Interventions
Etanercept, Lupus Treatment- Standard of Care, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Placebo, CB-839, everolimus
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Tucson, Arizona • Rogers, Arkansas • Los Angeles, California + 34 more
Conditions
Adult Kidney Wilms Tumor, Beckwith-Wiedemann Syndrome, Childhood Kidney Wilms Tumor, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Rhabdoid Tumor of the Kidney, Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor, Stage V Kidney Wilms Tumor
Interventions
Dactinomycin, Doxorubicin Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery, Vincristine Sulfate
Biological · Drug · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
146
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 111 more
Conditions
Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma, Malignant Uterine Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Malignant Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage III Bladder Cancer, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Breast Cancer, Stage IIIB Cervical Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Breast Cancer, Stage IIIC Ovarian Cancer, Stage IV Breast Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IVA Bladder Cancer, Stage IVA Cervical Cancer, Stage IVB Bladder Cancer, Stage IVB Cervical Cancer
Interventions
Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Active, not recruiting Phase 1Phase 2 Interventional

A Study of NDI 1150-101 in Patients With Solid Tumors

NCT05128487
Conditions
Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
Interventions
NDI-101150, Pembrolizumab
Drug
Lead sponsor
Nimbus Saturn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
19
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 15 more
Conditions
Kidney Cancer
Interventions
motexafin gadolinium, sunitinib malate, comparative genomic hybridization, gene expression analysis, mutation analysis, polymorphism analysis, immunohistochemistry staining method, iodine I-124 girentuximab, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Metastatic Renal Cell Carcinoma ( mRCC), OligoProgressive Metastatic Disease
Interventions
IMSA101
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Breast Cancer, Lung Cancer, Colon Cancer, Pancreatic Cancer, Head and Neck Cancer, Kidney Cancer, Sarcoma, Hepatocellular Cancer
Interventions
Pazopanib, Ixabepilone
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Renal Cell Carcinoma
Interventions
Axitinib, MK-3475
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
19
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 7 more
Conditions
Renal Cell Carcinoma
Interventions
Erlotinib hydrochloride, Sirolimus
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Prostate Cancer, Kidney Cancer
Interventions
High intensity approach, Low intensity approach
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Chambersburg, Pennsylvania
Conditions
Renal Cell Cancer
Interventions
ABT-751
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
19
States / cities
Tucson, Arizona • Los Angeles, California • Montebello, California + 16 more
Conditions
Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine, mycophenolate mofetil, stem cell transplantation, total body irradiation, filgrastim
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Metastatic Cancer, Recurrent Cancer, Solid Tumor, Renal Cell Carcinoma, Urothelial Carcinoma, NSCLC, Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
IRX 2, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan, Pembrolizumab, Placebo
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
37
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 31 more
Conditions
Carcinoma, Renal Cell
Interventions
Tivozanib hydrochloride, Sorafenib
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
56
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma, Small-cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Merkel Cell Carcinoma
Interventions
GEN-011, IL-2, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Gilbert, Arizona • Tampa, Florida • Chicago, Illinois + 4 more
Conditions
Renal Cell Carcinoma
Interventions
autologous human tumor-derived HSPPC-96
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
39
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 36 more
Conditions
Renal Cancer
Interventions
(EORTC QLQ-C30) questionnaire, EuroQol EQ-5D 7-item questionnaire
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York + 3 more
Conditions
Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
Interventions
MT-8421, Nivolumab
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Lafayette, Indiana • St Louis, Missouri + 2 more
Conditions
Carcinoma, Renal Cell
Interventions
GW786034, lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Interventions
Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Alexander City, Alabama • Anchorage, Alaska • Springdale, Arkansas + 5 more
Conditions
Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer, Inflammatory Bowel Diseases, Stem Cell Transplant, Organ Transplant, Diabetes Mellitus, Type 1, Cystic Fibrosis
Interventions
PiCASO Intervention Group, Sham Comparator: Attention Control Group
Behavioral
Lead sponsor
Duke University
Other
Eligibility
16 Years to 22 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Advanced Renal Cell Carcinoma
Interventions
MEDI5752, Axitinib, Lenvatinib
Biological · Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Fort Myers, Florida • St Louis, Missouri + 4 more